Additionally, it was found that the lymphangiogenesis induced by the interaction of VEGF-C and VEGFR-3 enhances the recruitment of naïve CD4+ and CD8+ T cells to primary tumors, which led to increased tumor rejection combined with immunotherapies (Fankhauser et al., 2017; Farnsworth et al., 2018). Here, VEGFC is linked to neoplasm.